Symbols / CYTK
CYTK Chart
About
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 8.57B |
| Enterprise Value | 8.96B | Income | -751.94M | Sales | 87.21M |
| Book/sh | -4.26 | Cash/sh | 7.87 | Dividend Yield | — |
| Payout | 0.00% | Employees | 498 | IPO | — |
| P/E | — | Forward P/E | -11.30 | PEG | — |
| P/S | 98.28 | P/B | -16.45 | P/C | — |
| EV/EBITDA | -15.90 | EV/Sales | 102.72 | Quick Ratio | 6.78 |
| Current Ratio | 6.88 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -6.30 | EPS next Y | -6.20 | EPS Growth | — |
| Revenue Growth | 3.18% | Earnings | 2026-02-24 | ROA | -24.93% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -86.13% | Profit Margin | 0.00% | Shs Outstand | 122.26M |
| Shs Float | 121.34M | Short Float | 14.10% | Short Ratio | 7.40 |
| Short Interest | — | 52W High | 70.98 | 52W Low | 29.31 |
| Beta | 0.55 | Avg Volume | 1.86M | Volume | 1.94M |
| Target Price | $90.39 | Recom | Buy | Prev Close | $68.26 |
| Price | $70.10 | Change | 2.70% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$90.39
Mean price target
2. Current target
$70.10
Latest analyst target
3. DCF / Fair value
$-47.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$70.10
Low
$61.00
High
$136.00
Mean
$90.39
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-20 | main | RBC Capital | Outperform → Outperform | $101 |
| 2026-02-03 | main | Truist Securities | Buy → Buy | $92 |
| 2026-01-21 | main | B. Riley Securities | Buy → Buy | $108 |
| 2026-01-21 | reit | RBC Capital | Outperform → Outperform | $95 |
| 2026-01-20 | main | JP Morgan | Overweight → Overweight | $74 |
| 2025-12-23 | main | Morgan Stanley | Overweight → Overweight | $71 |
| 2025-12-22 | main | RBC Capital | Outperform → Outperform | $95 |
| 2025-12-22 | main | Barclays | Overweight → Overweight | $87 |
| 2025-12-22 | main | Citizens | Market Outperform → Market Outperform | $88 |
| 2025-12-22 | main | Needham | Buy → Buy | $84 |
| 2025-12-22 | main | HC Wainwright & Co. | Buy → Buy | $136 |
| 2025-12-19 | up | Goldman Sachs | Neutral → Buy | $95 |
| 2025-12-12 | reit | Needham | Buy → Buy | $72 |
| 2025-11-11 | main | RBC Capital | Outperform → Outperform | $87 |
| 2025-11-10 | reit | B. Riley Securities | Buy → Buy | $90 |
| 2025-10-06 | main | Barclays | Overweight → Overweight | $82 |
| 2025-10-02 | main | B of A Securities | Neutral → Neutral | $56 |
| 2025-09-29 | reit | HC Wainwright & Co. | Buy → Buy | $120 |
| 2025-09-22 | main | B. Riley Securities | Buy → Buy | $80 |
| 2025-09-22 | reit | HC Wainwright & Co. | Buy → Buy | $120 |
- Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Wed, 25 Feb 2026 00
- Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Powerhouse with 33% Potential Upside - DirectorsTalk Interviews Mon, 23 Feb 2026 20
- Cytokinetics Q4 2025 Earnings Call Transcript - MarketBeat ue, 24 Feb 2026 23
- Is It Too Late To Reassess Cytokinetics (CYTK) After Its 41% One Year Gain? - simplywall.st Mon, 23 Feb 2026 21
- Cytokinetics (CYTK) Price Target Raised by RBC Capital on Februa - GuruFocus Fri, 20 Feb 2026 15
- Cytokinetics Q4 Earnings Summary & Key Takeaways - Benzinga ue, 24 Feb 2026 21
- Earnings Flash (CYTK) Cytokinetics Posts Q4 Loss $-1.50, vs. FactSet Est of Loss of $-1.56 - marketscreener.com ue, 24 Feb 2026 21
- Liquidity Mapping Around (CYTK) Price Events - Stock Traders Daily hu, 19 Feb 2026 20
- Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo - Zacks Investment Research Wed, 18 Feb 2026 14
- New MYQORZO drug wins EU nod to treat symptomatic obstructive HCM - Stock Titan ue, 17 Feb 2026 12
- Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline - Finviz ue, 17 Feb 2026 16
- Insider Sale: EVP of $CYTK Sells 1,042 Shares | CYTK Stock News - Quiver Quantitative Mon, 08 Dec 2025 08
- Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space - Yahoo Finance hu, 19 Feb 2026 19
- Cytokinetics, Incorporated (CYTK) Stock Analysis: A 35.74% Potential Upside Fuels Investor Interest - DirectorsTalk Interviews Mon, 16 Feb 2026 08
- New campaigns give HCM patients, families stronger voices - Stock Titan Mon, 09 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 15000 | 928950 | — | Sale at price 61.93 per share. | CALLOS ANDREW | Officer | — | 2026-02-05 00:00:00 | D |
| 1 | 15000 | 348900 | — | Conversion of Exercise of derivative security at price 23.26 per share. | CALLOS ANDREW | Officer | — | 2026-02-05 00:00:00 | D |
| 2 | 886 | 55021 | — | Sale at price 62.10 per share. | CALLOS ANDREW | Officer | — | 2026-02-02 00:00:00 | D |
| 3 | 886 | 33340 | — | Conversion of Exercise of derivative security at price 37.63 per share. | CALLOS ANDREW | Officer | — | 2026-02-02 00:00:00 | D |
| 4 | 98 | 6217 | — | Stock Award(Grant) at price 63.44 per share. | WIERENGA WENDELL | Director | — | 2026-01-15 00:00:00 | D |
| 5 | 197 | 12498 | — | Stock Award(Grant) at price 63.44 per share. | KAYE EDWARD M | Director | — | 2026-01-15 00:00:00 | D |
| 6 | 334 | 21189 | — | Stock Award(Grant) at price 63.44 per share. | HENDERSON JOHN TANNAHILL | Director | — | 2026-01-15 00:00:00 | D |
| 7 | 197 | 12498 | — | Stock Award(Grant) at price 63.44 per share. | DALY JAMES M. | Director | — | 2026-01-15 00:00:00 | D |
| 8 | 98 | 6217 | — | Stock Award(Grant) at price 63.44 per share. | WYSENSKI NANCY J | Director | — | 2026-01-15 00:00:00 | D |
| 9 | 197 | 12498 | — | Stock Award(Grant) at price 63.44 per share. | HARRINGTON ROBERT ARTHUR | Director | — | 2026-01-15 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -494.78M | -456.68M | -307.05M | -183.71M |
| TotalUnusualItems | 1.30M | 0.00 | -24.94M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 1.30M | 0.00 | -24.94M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -589.53M | -526.24M | -388.95M | -215.31M |
| ReconciledDepreciation | 9.53M | 11.89M | 5.81M | 2.28M |
| ReconciledCostOfRevenue | 339.41M | 330.12M | 240.81M | 159.94M |
| EBITDA | -493.48M | -456.68M | -331.99M | -183.71M |
| EBIT | -503.01M | -468.58M | -337.80M | -185.98M |
| NetInterestIncome | -34.98M | -30.04M | -39.81M | -29.00M |
| InterestExpense | 86.51M | 57.67M | 51.16M | 29.33M |
| InterestIncome | 51.53M | 27.63M | 11.34M | 331.00K |
| NormalizedIncome | -590.83M | -526.24M | -364.02M | -215.31M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -589.53M | -526.24M | -388.95M | -215.31M |
| TotalExpenses | 554.72M | 503.74M | 418.79M | 256.74M |
| TotalOperatingIncomeAsReported | -536.25M | -496.20M | -324.20M | -186.31M |
| DilutedAverageShares | 111.98M | 96.52M | 89.83M | 76.89M |
| BasicAverageShares | 111.98M | 96.52M | 89.83M | 76.89M |
| DilutedEPS | -5.26 | -5.45 | -4.33 | -2.80 |
| BasicEPS | -5.26 | -5.45 | -4.33 | -2.80 |
| DilutedNIAvailtoComStockholders | -589.53M | -526.24M | -388.95M | -215.31M |
| NetIncomeCommonStockholders | -589.53M | -526.24M | -388.95M | -215.31M |
| NetIncome | -589.53M | -526.24M | -388.95M | -215.31M |
| NetIncomeIncludingNoncontrollingInterests | -589.53M | -526.24M | -388.95M | -215.31M |
| NetIncomeContinuousOperations | -589.53M | -526.24M | -388.95M | -215.31M |
| PretaxIncome | -589.53M | -526.24M | -388.95M | -215.31M |
| OtherIncomeExpense | -18.30M | -24.94M | ||
| OtherNonOperatingIncomeExpenses | -19.60M | |||
| SpecialIncomeCharges | 0.00 | 0.00 | -24.94M | 0.00 |
| OtherSpecialCharges | 24.94M | |||
| GainOnSaleOfSecurity | 1.30M | |||
| NetNonOperatingInterestIncomeExpense | -34.98M | -30.04M | -39.81M | -29.00M |
| InterestExpenseNonOperating | 86.51M | 57.67M | 51.16M | 29.33M |
| InterestIncomeNonOperating | 51.53M | 27.63M | 11.34M | 331.00K |
| OperatingIncome | -536.25M | -496.20M | -324.20M | -186.31M |
| OperatingExpense | 215.31M | 173.61M | 177.98M | 96.80M |
| ResearchAndDevelopment | 159.94M | |||
| SellingGeneralAndAdministration | 215.31M | 173.61M | 177.98M | 96.80M |
| GeneralAndAdministrativeExpense | 215.31M | 173.61M | 177.98M | 96.80M |
| OtherGandA | 215.31M | 173.61M | 177.98M | 96.80M |
| GrossProfit | -320.93M | -322.59M | -146.22M | -89.51M |
| CostOfRevenue | 339.41M | 330.12M | 240.81M | 159.94M |
| TotalRevenue | 18.47M | 7.53M | 94.59M | 70.43M |
| OperatingRevenue | 18.47M | 7.53M | 94.59M | 70.43M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 118.21M | 101.64M | 94.83M | 84.80M |
| ShareIssued | 118.21M | 101.64M | 94.83M | 84.80M |
| NetDebt | 562.26M | 504.43M | 544.99M | 30.17M |
| TotalDebt | 788.68M | 755.77M | 750.30M | 269.93M |
| TangibleBookValue | -135.37M | -386.32M | -107.90M | 243.86M |
| InvestedCapital | 521.75M | 231.13M | 502.68M | 386.70M |
| WorkingCapital | 928.27M | 525.37M | 710.57M | 463.81M |
| NetTangibleAssets | -135.37M | -386.32M | -107.90M | 243.86M |
| CapitalLeaseObligations | 131.56M | 138.32M | 139.72M | 127.09M |
| CommonStockEquity | -135.37M | -386.32M | -107.90M | 243.86M |
| TotalCapitalization | 510.23M | 221.05M | 501.72M | 386.70M |
| TotalEquityGrossMinorityInterest | -135.37M | -386.32M | -107.90M | 243.86M |
| StockholdersEquity | -135.37M | -386.32M | -107.90M | 243.86M |
| GainsLossesNotAffectingRetainedEarnings | 2.40M | -10.00K | -3.59M | -869.00K |
| OtherEquityAdjustments | 2.40M | -10.00K | -3.59M | -869.00K |
| RetainedEarnings | -2.70B | -2.11B | -1.59B | -1.21B |
| AdditionalPaidInCapital | 2.56B | 1.73B | 1.48B | 1.45B |
| CapitalStock | 118.00K | 102.00K | 94.00K | 84.00K |
| CommonStock | 118.00K | 102.00K | 94.00K | 84.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.54B | 1.21B | 1.12B | 597.46M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.36B | 1.11B | 1.04B | 525.60M |
| OtherNonCurrentLiabilities | 599.19M | 380.16M | 301.55M | 183.53M |
| NonCurrentDeferredLiabilities | 0.00 | 87.00M | ||
| NonCurrentDeferredRevenue | 0.00 | 87.00M | ||
| LongTermDebtAndCapitalLeaseObligation | 758.18M | 727.80M | 736.51M | 255.07M |
| LongTermCapitalLeaseObligation | 112.58M | 120.43M | 126.89M | 112.23M |
| LongTermDebt | 645.60M | 607.37M | 609.62M | 142.84M |
| CurrentLiabilities | 179.67M | 102.68M | 84.62M | 71.86M |
| OtherCurrentLiabilities | 21.11M | 10.56M | 1.12M | 1.54M |
| CurrentDeferredLiabilities | 52.37M | 0.00 | ||
| CurrentDeferredRevenue | 52.37M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 30.50M | 27.97M | 13.79M | 14.86M |
| CurrentCapitalLeaseObligation | 18.98M | 17.89M | 12.83M | 14.86M |
| CurrentDebt | 11.52M | 10.08M | 958.00K | |
| OtherCurrentBorrowings | 11.52M | 10.08M | 958.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 35.13M | 29.25M | 21.77M | 14.93M |
| PayablesAndAccruedExpenses | 40.56M | 34.89M | 47.94M | 40.53M |
| CurrentAccruedExpenses | 20.19M | 13.39M | 22.33M | 19.44M |
| Payables | 20.37M | 21.51M | 25.61M | 21.09M |
| AccountsPayable | 20.37M | 21.51M | 25.61M | 21.09M |
| TotalAssets | 1.40B | 824.32M | 1.01B | 841.32M |
| TotalNonCurrentAssets | 293.73M | 196.26M | 219.59M | 305.65M |
| OtherNonCurrentAssets | 7.71M | 8.00M | 9.69M | 7.19M |
| InvestmentsAndAdvances | 145.06M | 40.53M | 46.71M | 152.05M |
| InvestmentinFinancialAssets | 145.06M | 40.53M | 46.71M | 152.05M |
| AvailableForSaleSecurities | 145.06M | 40.53M | 46.71M | 152.05M |
| NetPPE | 140.97M | 147.74M | 163.19M | 146.41M |
| AccumulatedDepreciation | -37.18M | -28.35M | -17.09M | -16.19M |
| GrossPPE | 178.15M | 176.08M | 180.28M | 162.60M |
| Leases | 66.87M | 66.87M | 65.91M | 60.34M |
| ConstructionInProgress | 4.07M | 220.00K | 741.00K | 224.00K |
| OtherProperties | 97.79M | 99.67M | 103.67M | 93.38M |
| MachineryFurnitureEquipment | 9.42M | 9.32M | 9.96M | 8.65M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.11B | 628.05M | 795.19M | 535.67M |
| OtherCurrentAssets | 15.28M | 11.94M | 12.46M | 12.21M |
| PrepaidAssets | 12.21M | |||
| Receivables | 16.65M | 1.28M | 147.00K | 51.82M |
| AccountsReceivable | 16.65M | 1.28M | 147.00K | 51.82M |
| CashCashEquivalentsAndShortTermInvestments | 1.08B | 614.82M | 782.58M | 471.64M |
| OtherShortTermInvestments | 981.16M | 501.80M | 717.00M | 358.97M |
| CashAndCashEquivalents | 94.86M | 113.02M | 65.58M | 112.67M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -399.80M | -415.75M | -310.85M | -191.39M |
| RepaymentOfDebt | -9.62M | -858.00K | -188.93M | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | 523.59M | 0.00 |
| IssuanceOfCapitalStock | 706.84M | 164.23M | 0.00 | 312.05M |
| CapitalExpenditure | -3.91M | -1.42M | -11.34M | -48.87M |
| InterestPaidSupplementalData | 25.97M | 10.29M | 15.16M | 9.18M |
| EndCashPosition | 95.23M | 113.40M | 67.18M | 112.67M |
| BeginningCashPosition | 113.40M | 67.18M | 112.67M | 82.98M |
| EffectOfExchangeRateChanges | 209.00K | -20.00K | 0.00 | 0.00 |
| ChangesInCash | -18.38M | 46.24M | -45.48M | 29.68M |
| FinancingCashFlow | 930.61M | 221.32M | 516.17M | 319.98M |
| CashFlowFromContinuingFinancingActivities | 930.61M | 221.32M | 516.17M | 319.98M |
| NetOtherFinancingCharges | 180.37M | 39.48M | 163.96M | -4.45M |
| ProceedsFromStockOptionExercised | 53.02M | 18.46M | 17.54M | 12.38M |
| NetCommonStockIssuance | 706.84M | 164.23M | 0.00 | 312.05M |
| CommonStockIssuance | 706.84M | 164.23M | 0.00 | 312.05M |
| NetIssuancePaymentsOfDebt | -9.62M | -858.00K | 334.66M | 0.00 |
| NetLongTermDebtIssuance | -9.62M | -858.00K | 334.66M | 0.00 |
| LongTermDebtPayments | -9.62M | -858.00K | -188.93M | 0.00 |
| LongTermDebtIssuance | 0.00 | 0.00 | 523.59M | 0.00 |
| InvestingCashFlow | -553.10M | 239.25M | -262.13M | -147.78M |
| CashFlowFromContinuingInvestingActivities | -553.10M | 239.25M | -262.13M | -147.78M |
| NetInvestmentPurchaseAndSale | -549.19M | 240.67M | -250.80M | -98.91M |
| SaleOfInvestment | 744.23M | 875.88M | 604.59M | 426.14M |
| PurchaseOfInvestment | -1.29B | -635.21M | -855.39M | -525.04M |
| NetPPEPurchaseAndSale | -3.91M | -1.42M | -11.34M | -48.87M |
| PurchaseOfPPE | -3.91M | -1.42M | -11.34M | -48.87M |
| OperatingCashFlow | -395.89M | -414.33M | -299.52M | -142.52M |
| CashFlowFromContinuingOperatingActivities | -395.89M | -414.33M | -299.52M | -142.52M |
| ChangeInWorkingCapital | 35.66M | 3.09M | -24.70M | 8.46M |
| ChangeInOtherWorkingCapital | 52.37M | -87.00M | ||
| ChangeInOtherCurrentLiabilities | -8.60M | -10.99M | -2.33M | 47.12M |
| ChangeInPayablesAndAccruedExpense | 9.70M | 13.62M | 15.37M | 16.11M |
| ChangeInAccruedExpense | 14.18M | 17.10M | 10.84M | 15.06M |
| ChangeInPayable | -4.48M | -3.48M | 4.52M | 1.05M |
| ChangeInAccountPayable | -4.48M | -3.48M | 4.52M | 1.05M |
| ChangeInPrepaidAssets | -2.44M | 1.60M | -7.41M | -7.38M |
| ChangeInReceivables | -15.37M | -1.14M | 56.67M | -47.40M |
| ChangesInAccountReceivables | -15.37M | -1.14M | 56.67M | -47.40M |
| OtherNonCashItems | 51.88M | 24.83M | 57.68M | 32.38M |
| StockBasedCompensation | 97.84M | 72.06M | 47.85M | 26.83M |
| AssetImpairmentCharge | 0.00 | 0.00 | 2.84M | |
| DepreciationAmortizationDepletion | 9.53M | 11.89M | 5.81M | 2.28M |
| DepreciationAndAmortization | 9.53M | 11.89M | 5.81M | 2.28M |
| Depreciation | 9.53M | 11.89M | 5.81M | 2.28M |
| OperatingGainsLosses | -1.27M | 35.00K | 2.80M | |
| GainLossOnInvestmentSecurities | -1.32M | 35.00K | 107.00K | |
| GainLossOnSaleOfPPE | 45.00K | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | -589.53M | -526.24M | -388.95M | -215.31M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CYTK
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|